The Post-Shutdown Quality Lowdown
Executive Summary
Quality oversight activity began ramping back up after the partial US government shutdown, even as EU oversight activities entered into a Brexit-related slowdown.
You may also be interested in...
The Quality Lowdown: Diversion, Cross-Contamination And PR Mix-Ups
McKesson meets with US FDA over opioid diversion warning letter, while UK MHRA takes risk-based approach to cross-contamination recalls and firm says it’s the other Guardian Pharmacy.
Brexit Won't Impair Pharmacovigilence 'Fundamentals' – DIA Panel
MHRA pharmacovigilance leader says global safety efforts will not lose UK expertise.
Pfizer Eyes Three Oncology Biosimilar Launches In 2019 As Sterile Injectables Problems Persist
Pfizer’s long-standing sterile injectable supply and manufacturing issues pummelled respective sales in the US in 2018. But the US-based multinational is eyeing a string of oncology biosimilar launches in 2019, which could see biosimilar sales tick past US$1 billion.